Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03665129
Title IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors (STELLAR-001)
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Innate Pharma
Age Groups: adult | senior
Covered Countries USA | FRA

Facility Status City State Zip Country Details
James Graham Brown Cancer Center Louisville Kentucky 40202 United States Details
Park Nicollet Frauenshuh Cancer Center Saint Louis Park Minnesota 55426 United States Details
ICAHN School of Medicine at Mount Sinai New York New York 10029-6574 United States Details
Sarah Cannon Research Institute Nashville Tennessee 37203 United States Details
NEXT Oncology San Antonio Texas 78006 United States Details
Centre Georges-Francois Leclerc Dijon France Details
Centre Leon Berard Lyon 69373 France Details
Hôpital de la Timone- AP-HM Marseille France Details
Institut du Cancer de Montpellier Montpellier France Details
Centre Hospitalier Universitaire- Hôpital Nord Laennec Nantes France Details
Centre Eugène Marquis Rennes France Details
Institut Gustave Roussy Villejuif France Details
*Shaded cells indicate that there was no data available from for the field